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Abstract
Aberrant silencing of genes by DNA methylation contributes to cancer, yet how this process is 
initiated remains unclear. Using a murine model of inflammation-induced tumorigenesis, we tested 
the hypothesis that inflammation promotes recruitment of epigenetic proteins to chromatin, 
initiating methylation and gene silencing in tumors. Compared to normal epithelium and non-
inflammation-induced tumors, inflammation-induced tumors gained DNA methylation at CpG 
islands, some of which are associated with putative tumor suppressor genes. Hypermethylated 
genes exhibited enrichment of repressive chromatin marks and reduced expression prior to 
tumorigenesis, at a time point coinciding with peak levels of inflammation-associated DNA 
damage. Loss of MutS homolog 2 (MSH2), a mismatch repair (MMR) protein, abrogated early 
inflammation-induced epigenetic alterations and DNA hypermethylation alterations observed in 
inflammation-induced tumors. These results indicate that early epigenetic alterations initiated by 
inflammation and MMR proteins lead to gene silencing during tumorigenesis, revealing a novel 
mechanism of epigenetic alterations in inflammation-driven cancer. Understanding such 
mechanisms will inform development of pharmacotherapies to reduce carcinogenesis.
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Introduction
Approximately 25% of all cancers are associated with chronic inflammation (1). Colorectal 
cancer (CRC) is a substantial contributor to morbidity and mortality worldwide (2). 
Although the vast majority of CRC cases are sporadic, 5–10% of cases have been attributed 
to hereditary conditions (3). In addition to family history, several risk factors associated with 
CRC have been identified including age, inflammatory bowel disease, bacterial infection, 
obesity, excessive alcohol consumption, and smoking (4). Most of these risk factors are 
characterized by chronic inflammation (5). Moreover, nonsteroidal anti-inflammatory drug 
use was reported to reduce the risk of CRC, reinforcing the notion that inflammation is a 
central contributor to CRC development (6).
In addition to inflammation, genetic mutations and epigenetic alterations play a key role in 
driving CRC (7, 8). Several genetic mutations that contribute to the initiation of CRC have 
been identified and well characterized (9). Epigenetic alterations also contribute to CRC 
initiation and progression. DNA methylation is the most extensively studied epigenetic 
alteration in cancer and cancer cells exhibit a global loss of DNA methylation that is thought 
to lead to genomic instability (8). Additionally, there is concurrent hypermethylation at 
distinct regions, often within promoter CpG islands of tumor suppressor genes (TSGs) (8). 
Such hypermethylation can lead to TSG silencing and contribute to cancer. While the 
fundamental importance of cancer-specific DNA methylation alterations is clear, how they 
are initiated is not well understood.
Our group previously demonstrated that treatment of cancer cells with the reactive oxygen 
species (ROS) hydrogen peroxide (H202) causes localization of an epigenetic silencing 
complex containing DNA methyltransferases DNMT1 and DNMT3B, and the chromatin 
silencers Sirtuin-1 (SIRT1) and Enhancer of Zeste-2 (EZH2) to sites of damaged chromatin. 
Notably, there was enrichment of these silencing proteins at the promoter CpG islands of 
TSGs, resulting in reduced gene expression (10). Based on these findings, we hypothesized 
that inflammation would induce similar events in vivo.
In the present study, we uncover a novel mechanism responsible for initiating cancer-
relevant epigenetic alterations in a murine model of inflammation-induced tumorigenesis. 
Our results demonstrate that epigenetic alterations that occur during inflammation-driven 
tumorigenesis are distinct from those that occur during inflammation-independent 
tumorigenesis. To our knowledge, we are the first to demonstrate the involvement of the 
mismatch repair (MMR) pathway in initiating epigenetic alterations during inflammation-
induced tumorigenesis. Since inflammation and epigenetic alterations are critical in the 
development of many cancer types and diseases, a deeper understanding of the interplay 
between these two factors, as gained from this study, is broadly relevant.
Materials and Methods
Animal model
C57BL/6J (Jackson labs) and MinApcΔ716+/− mice were handled and inoculated with ETBF 
as in Wu et al. (2009) (11). Msh2l/lVC are a result of crossing B6.Cg-MSH2tm2.1Rak/J and 
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B6.Cg-Tg(Vil1-cre)997Gum/J mice (Jackson Labs) to create mice homozygous for 
MSH2tm2.1Rak and expressing the Vil1-cre transgene. Littermates not expressing Vil1-cre 
were used as WT controls. Msh2l/lVC/Min are the result of crossing Msh2l/lVC and 
MinApcΔ716+/− mice. For all experiments both males and females were used, mice were 
randomized between mock and ETBF groups, and mice of different genotypes were 
cohoused. Individual tumors were removed from dissected colons with the aid of a 
dissecting microscope and stored at −80°C until further analysis. Distal (0–2 cm measured 
from the rectum) and proximal (feathered portion adjacent to ceacum) epithelium was 
collected by scraping the mucosal surface of the dissected colon (after removal of any 
tumors), washed three times in PBS, and then subjected to the indicated protocol. Such 
scraping has been shown by others to be an effective method to obtain samples of intestinal 
epithelial cells (12). All mouse experiments were covered under protocol number 16-027, 
which was approved by the Indiana University Bloomington Animal Care and Use 
Committee in accordance with the Association for Assessment and Accreditation of 
Laboratory Animal Care International.
Methyl CpG binding domain (MBD)-seq
DNA was isolated from tumors or epithelium using the QIAamp DNA mini kit (Qiagen) 
following the manufacturer’s protocol. To identify differentially methylated regions 
(DMRs), MBD enrichment was performed from DNA from epithelium collected from 
different mice (n=5 WT/Min mock, n=3 WT/Min ETBF, n=3 Msh2l/lVC/Min mock) or 
individual tumors (n= 3 WT/Min mock, n=7 WT/Min ETBF, n=3 Msh2l/lVC/Min mock, 
n=3 Msh2l/lVC/Min ETBF) using Diagenode’s MethylCap kit. Libraries were prepared 
following Bioo Scientific’s Methyl Sequencing kit. Single-end 75 bp sequencing was 
performed using an Illumina Nextseq. Z-scores were calculated using a 500bp fixed sized 
bin spanning CpG islands based on the distribution of coverage from uniquely mapped 
reads. Z-ratios were derived from the comparison of z-scores for the different sample types 
for the 500bp regions. See Supplemental Methods for more detail.
Pyrosequencing and Quantitative Methylation Specific PCR (qMSP)
DNA was bisulfite treated (EZ DNA methylation-Gold kit, Zymo Research) and used for 
pyrosequencing. qMSP assays were first tested using a standard curve of bisulfite treated 
mixtures of unmethylated and methylated DNA (data not shown). Only methylated DNA 
assays with little to no amplification of unmethylated samples, close to 100% efficiency and 
R2 close to 1 were used further. See Table S1 for assays and primers used.
Gene expression
RNA was prepared from epithelium or tumors using Trizol followed by cleanup with a 
RNeasy kit (Qiagen). cDNA was prepared and qPCR was done using TaqMan assays (see 
Table S1 for assays used). Expression of candidate genes was normalized to expression of a 
housekeeping gene (PPIA or 18S).
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Tight chromatin fractionation
Tight chromatin fractionation of washed epithelium was performed as described in Ding et 
al. (13). Blots presented are representative of three independent experiments.
Chromatin immunoprecipitation (ChIP)
ChIP was performed using anti-H3K27me3 (Diagenode) or anti-EZH2 (D2C9-Cell 
Signaling Technologies) and the iDeal CHIP-Seq kit for histones and transcription factors 
(Diagenode) according to the manufacturer’s instructions.
CoIP
coIPs were performed from nuclear extracts that were treated with oligoamines to release 
chromatin-bound proteins as described in Ding et al. (13). Antibodies used were rabbit IgG 
(Millipore) and anti-EZH2 (5246-Cell Signaling Technologies). Blots presented are 
representative of two independent experiments.
MSI
MSI analysis was performed as in Woerner et al. (14). MSI was determined by comparing 
DNA fragment analysis of mononucleotide markers in tumors relative to tail DNA from the 
same mouse.
16S microbiome sequencing
DNA was isolated from stool using the ZR Fecal DNA micro kit (Zymo Research). Libraries 
were made from 16S V1-V3 PCR amplicons from the stool DNA using the NEXTflex 16S 
V1-V3 kit (Bioo Scientific). 300 bp paired-end sequencing of pooled libraries was 
performed on a MiSeq. Read quality filtering was performed using mothur. AbundantOTU+ 
was used for clustering of sequences to Operational Taxonomic Units (OTUs) and further 
classification. MetagenomeSeq was used to determine differential abundance across samples 
using normalized OTU read counts. OTUs with significant (5% FDR) differential abundance 
between any of the sample groups were used to create the heatmap (65 OTUs).
Total CpG methylation
Total CpG methylation in DNA from epithelium and tumor samples was determined using 
an ELISA-based assay (MethylFlash Global DNA Methylation (5-mC) – Epigenetek).
Statistical Analysis
Expression data, densitometry, qMSP, and local ChIP are presented as the mean +/− standard 
error (SEM). These data are evaluated by one-tail t-test and considered statistically 
significant with a p-value < 0.05. Sample sizes are indicated in associated figure legends. 
MBD-seq statistical analysis is detailed in the Supplemental Methods.
Data availability
MBD and 16S sequencing data have been deposited at the Sequence Read Archive (SRA) 
data repository (project accession number SRP105286).
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Results
Inflammation-induced tumors have a unique DNA hypermethylation signature
Enterotoxigenic Bacteroides fragilis (ETBF) is a clinically relevant strain of B. fragilis (15). 
When Multiple intestinal neoplasia (Min) mice, which are heterozygous for mutant 
adenomatous polyposis coli (ApcΔ716), are infected with ETBF, tumors rapidly form at the 
site of inflammation, in the distal colon (11). Studies have demonstrated that inflammation-
induced tumors have unique DNA methylation alterations compared to uninflamed tissue 
therefore we evaluated DNA methylation in our model (16, 17). Min mice spontaneously 
develop rare colon tumors (18) allowing us to uniquely compare DNA methylation 
alterations of inflammation-induced ETBF tumors to methylation alterations of background 
Min (mock) tumors. Interestingly, relative to mock epithelium, the ETBF tumors compared 
to mock tumors had more hypermethylated DMRs (203 compared to 6) but fewer 
hypomethylated DMRs (194 compared to 700, Table 1, Figure 1A). Of the methylation gains 
that occurred in mock tumors, 5 overlap with the ETBF tumors (Table S2).
As Naumov et al. (19) demonstrated in human tumors, regions that gained methylation in 
ETBF tumors had low DNA methylation levels in mock epithelium (mean z-score of 0.4) 
whereas regions that lost methylation in ETBF or mock tumors had relatively high DNA 
methylation levels in mock epithelium (mean z-score 3.4 or 3.6, respectively) (Figure 1B). 
Both gains and losses occurred more often in CpG islands in exons or promoters of genes 
than introns, 3′ UTRs, or intragenic regions (Figure S1A). As expected, regions targeted for 
DNA hypermethylation were enriched for regions that are bivalent (containing both 
H3K4me3 and H3K27me3) in mouse embryonic stem cells (Figure S1B) (20–24).
Since chronic inflammation is known to induce DNA methylation changes in inflamed 
epithelium (16), we also assayed methylation changes in the distal colon epithelium of 
ETBF-infected mice (ETBF epithelium). ETBF epithelium had fewer hypermethylated 
DMRs in comparison to the ETBF tumors, but more than the mock epithelium and mock 
tumors (Table 1). Eleven of the 40 hypermethylated DMRs observed in the ETBF epithelium 
overlapped with those in the ETBF tumors (Table S2). When samples were clustered based 
on regions with DNA hypermethylation in tumors relative to mock epithelium, the ETBF 
epithelium clustered with the mock epithelium (Figure 1A). Interestingly, ETBF tumors 
clustered separately from the mock tumors and epithelium, suggesting that they have distinct 
methylation gains from the other samples.
Gene ontology (GO) analysis revealed that the genes associated with DMRs in the mock and 
ETBF tumors are involved in multiple biological processes many of which are associated 
with aspects of development, differentiation, and regulation of transcription (Table S3). 
Interestingly, several of the methylation gains observed in the ETBF tumors occurred within 
CpG islands of genes with known tumor suppressive function such as Hoxa5, Polg, Runx1, 
Runx3, CD37, Stx11, Tceb2, Lgr6, Cdx1, Fut4 (Figure 1C, Table S2) (25–34). CpG island 
hypermethylation at 18 out of 21 candidate genes in ETBF tumors versus mock epithelium 
were validated by pyrosequencing or qMSP (Figure 1D, 1E, S1C). No DNA methylation 
changes were detected in the promoter CpG island of Gapdh, a negative control (Figure 
S1C). 18 candidate genes are associated with human digestive organ tumors by Ingenuity 
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Pathway Analysis, demonstrating their relevance to human disease (Figure S1D). Runx3, 
Gata2, and Hoxa5 are also known to undergo aberrant DNA hypermethylation in human 
CRC (35, 36). qMSP analysis at candidate genes demonstrated an intermediate level of 
methylation in the ETBF epithelium, between that observed in the mock epithelium and 
ETBF tumor (Figure 1E) consistent with the data in Figure 1A.
As hypothesized, many genes containing hypermethylated promoter CpG islands in ETBF 
tumors also had reduced mRNA expression (Figure 1F). Additionally, several candidate 
genes had lower expression in ETBF epithelium compared to ETBF tumors, but higher 
expression compared to mock epithelium (Figure 1F), consistent with the methylation results 
in Figure 1E. Genes that contained hypermethylated CpG islands in non-promoter exons had 
increased gene expression as has been demonstrated previously (Figure S1E – Cldn4, Spi1, 
Stx11) (37). Overall, these findings indicate that ETBF tumors contain distinct cancer-
specific DNA hypermethylation alterations that distinguish them from mock and ETBF 
epithelium and mock tumors.
Early chromatin and transcriptional changes occur in genes that are DNA hypermethylated 
in inflammation-induced tumors
We hypothesized that ETBF-induced oxidative DNA damage may initiate epigenetic 
changes in the distal colon that ultimately result in the DNA hypermethylation observed in 
the inflammation-induced tumors. ETBF inoculation caused oxidative DNA damage 
(increased 8-oxoguanine) in the distal colon epithelium two days post-ETBF, which returned 
to background levels seven days post-ETBF (Figure 2A). We confirmed that the oxidative 
DNA damage was occurring in epithelial cells by assaying 8-oxoguanine in cells positive for 
the epithelial marker, EPCAM (Figure 2B).
The increased oxidative DNA damage observed in the distal colon epithelium two days post-
ETBF corresponded to a decrease in the mRNA expression of several candidate genes that 
were found to be hypermethylated in the ETBF tumors with expression levels returning back 
to normal seven days post-ETBF (Figure 2C). To address whether these changes occurred 
specifically in epithelial cells, we assessed the purity of our colon epithelial samples. Our 
samples contained approximately 84% EPCAM-positive cells and fewer than 2% CD45-
positive cells (Figure S2A), irrespective of ETBF treatment status. To probe this further we 
also cultured organoids from the distal colon epithelium following an established protocol 
(38), treated the epithelial organoids with H2O2 to mimic inflammation/oxidative damage in 
vitro, and examined expression of several candidate genes. Indeed, the candidate genes 
examined (Cdx1, Fut4, Hoxa5, Polg, Runx1) had reduced expression in response to 
oxidative stress (but not housekeeping genes Rpl0, Tbp), analogous to our in vivo results 
(Figure S2B). This result suggests that the changes observed in the colon epithelium in 
response to ETBF are likely occurring in epithelial cells and not an alternative cell type 
present in the mucosal surface.
Since EZH2 has been implicated in transcriptional repression at sites of oxidative DNA 
damage, we hypothesized that this protein would be enriched in the promoters of candidate 
genes that have reduced expression in the inflamed epithelium. Indeed, EZH2 was 
significantly enriched at several candidate genes in ETBF epithelium compared to mock 
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epithelium two days post-ETBF (Figure 2D). These regions also had enrichment of the 
repressive chromatin mark catalyzed by EZH2, trimethyl H3K27 (H3K27me3) (Figure 2E). 
These findings indicate that ETBF initiates early epigenetic and transcriptional alterations in 
several candidate genes from the MBD-seq dataset, and these changes are temporally and 
spatially associated with the oxidative DNA damage induced by ETBF.
MSH2 interacts with EZH2 and plays a key role in the initiation of early ETBF-induced 
epigenetic alterations
The MSH2-MSH6 heterodimer facilitates repair of clustered oxidative DNA lesions in a 
PCNA-dependent and S-phase-independent manner (39). In accordance with this finding, 
our group observed in vitro that MSH2 and MSH6 become more tightly bound to chromatin 
in response to oxidative damage and are indispensable for the recruitment of epigenetic 
silencing proteins to damaged chromatin (13). Therefore, we hypothesized that MSH2 and 
MSH6 contribute to early epigenetic alterations that occur in response to ETBF.
First, we demonstrated that EZH2 co-immunoprecipitated with DNMT1, MSH2, MSH6, and 
PCNA in the distal colon epithelium two days after ETBF, suggesting an interaction between 
epigenetic proteins and MMR proteins in response to ETBF (Figure 3A). This interaction 
did not occur in mock epithelium. SUZ12 and EED are known EZH2 interacting partners 
and are positive controls for the EZH2 co-IP.
To evaluate whether the MMR pathway is involved in ETBF-mediated epigenetic alterations, 
we examined mice that lack expression of Msh2 in intestinal epithelial cells. In Msh2l/lVC 
mice, the Msh2 gene is flanked by LoxP sequences and Cre recombinase is driven by a 
Villin promoter leading to deletion of Msh2 in intestinal epithelial cells (40). We verified 
that MSH2 protein is present in colon crypt cells in mock and ETBF inoculated wild type 
(WT) mice, but not in crypts from Msh2l/lVC mice (Figure 3B). In distal colon epithelium 
from WT ETBF-infected mice, epigenetic silencing proteins (EZH2, DNMT1, and SIRT1) 
and MMR proteins (MSH2, MSH6 and PCNA) have a higher affinity for chromatin than in 
mock mice (Figure 3C). This enhanced affinity occurred in the distal colon and not in the 
proximal colon that lacks ETBF-mediated inflammation. Loss of Msh2 reduced the ETBF-
mediated increase in binding of EZH2, DNMT1 and SIRT1 to chromatin (Figure 3C), 
highlighting the necessity of the MMR pathway in the response of epigenetic proteins to 
ETBF-induced damage. LAMB (Lamin-B), a loading control, was consistent across the 
samples. Levels of phosphorylated H2AX (γ-H2AX), a marker of DNA damage, were 
elevated in ETBF samples relative to mock samples. Interestingly, γ-H2AX levels were 
consistently higher in mock epithelium from Msh2l/lVC than WT mice, corresponding to a 
relative increase in binding of EZH2, SIRT1 and PCNA to chromatin. Moreover we 
examined the effect of loss of Msh2 on mRNA expression of several candidate genes and 
their expression was unaffected by ETBF in Msh2l/lVC mice (Figure 3D, S3A).
To rule out the possibility that loss of Msh2 alters the initial immune response to ETBF we 
examined the expression of several cytokines in response to ETBF two and seven days post-
infection and found that their expression was unaltered by loss of Msh2 (Figure S3B, C). 
Cell proliferation measured by Ki-67 staining and phosphorylation of STAT-3 was also 
unaffected by loss of Msh2 (Figure S3D, E). ETBF-infected Msh2l/lVC mice also have 
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similar numbers of γ-H2AX foci per crypt compared to ETBF-infected WT mice (Figure 
3E). Collectively, these findings implicate a role for MSH2 in initiating early epigenetic and 
transcriptional alterations observed in the inflamed colon epithelium of mice two days post-
ETBF.
Loss of Msh2 does not alter the background microbiota composition
It is possible that an alteration of the microbiota composition caused by loss of Msh2 could 
explain reduced ETBF-induced epigenetic alterations in Msh2l/lVC mice. Therefore, we 
examined whether loss of Msh2 alters the initial or ETBF-induced intestinal microbiota 
composition. 16S ribosomal RNA gene sequencing was performed on stool DNA and 
sequences were clustered into OTUs. Principal component analysis (PCA) and hierarchical 
clustering analysis based on the OTUs that had significantly differential abundance among 
the sample types revealed a high degree of similarity between the bacterial populations 
present in stool from mock-infected mice, regardless of genotype (Figure 4A and B). None 
of the OTUs were significantly different between the mock groups, suggesting that loss of 
Msh2 does not alter the background microbiota composition (Table S4). There was 
separation between samples from ETBF-infected and mock-infected mice, irrespective of 
genotype (Figure 4A and B, Table S4). PCA revealed a small degree of separation between 
ETBF-infected WT/Min versus ETBF-infected Msh2l/lVC/Min samples suggesting that loss 
of Msh2 might impact the ETBF-induced microbiota (Figure 4A and B, Table S4). However, 
loss of Msh2 correlates with a significant increased abundance of ETBF (Figure 4C) and 
colony formation units of ETBF per gram of stool (Figure S4), ruling out the possibility that 
loss of Msh2 reduces ETBF-mediated epigenetic alterations by reducing the abundance of 
ETBF. Altogether, loss of Msh2 did not alter the background microbiota of these mice, 
although it does alter the relative abundance of some bacterial populations upon ETBF-
infection.
Loss of Msh2 in intestinal epithelial cells caused an increase in inflammation-induced 
tumors with microsatellite instability
Although loss of Msh2 reduced early ETBF-induced epigenetic alterations (Figure 3), 
sporadic and germline mutations in the MMR pathway are commonly implicated in CRC 
pathogenesis (4). Therefore, we examined the effect of Msh2 deletion from intestinal 
epithelial cells on tumorigenesis in our model. Mock Msh2l/lVC/Min mice were similar to 
uninfected WT/Min mice in terms of tumor burden (Figure 4D). Interestingly, ETBF-
infected Msh2l/lVC/Min mice developed significantly more tumors in the distal colon than 
the WT/Min mice infected with ETBF, but the same regions had the highest number of 
tumors in both sets of mice (Figure 4D).
The Th17/STAT-3 immune response drives ETBF-mediated tumorigenesis in Min mice (11). 
Msh2 deletion did not alter ETBF-induced phosphorylation of STAT-3 in ETBF-induced 
tumors (Figure 4E). Furthermore, inactivation of APC leads to constitutive activation of the 
WNT/β-CATENIN signaling pathway in tumors in Min mice. Loss of Msh2 did not alter the 
magnitude of increase in levels of β-CATENIN or PCNA, a marker of proliferation, in 
ETBF-induced tumors (Figure 4E).
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Mutations in MMR genes are known to cause genomic instability by altering the length of 
repetitive DNA sequences known as microsatellites (4). Interestingly, the mock and ETBF 
Msh2l/lVC/Min tumors tested had microsatellite instability (MSI) whereas most tumors from 
the WT/Min mice were microsatellite stable (MSS) (9/11) (Table 2). These results are 
consistent with the observation in humans that mutated MSH2 can lead to colon 
tumorigenesis (4) and suggest that ETBF-induced tumors from Msh2-deficient mice are 
more genetically unstable than ETBF-induced tumors from Msh2-sufficient mice.
Loss of Msh2 decreases CpG island hypermethylation and restores expression of 
candidate TSGs
We initially demonstrated that Min ETBF tumors have a unique hypermethylation signature 
(Figure 1, Table 1). Since the Msh2l/lVC/Min mice still developed tumors in response to 
ETBF, this model provided us with a unique tool to answer the question: is MSH2 required 
for ETBF-induced tumor-specific DNA hypermethylation alterations during tumorigenesis? 
Therefore, we examined the effect of Msh2 deletion on methylation in ETBF tumors using 
MBD-seq. Importantly, loss of Msh2 dramatically reduced ETBF-mediated 
hypermethylation alterations with the Msh2l/lVC/Min ETBF tumors having only 11 DNA 
hypermethylated regions relative to Msh2l/lVC/Min mock epithelium (Figure 5A and B, 
Table S2). When samples are clustered using regions with DNA hypermethylation in tumors 
relative to the respective mock epithelium, the two mock epitheliums cluster together and the 
Msh2l/lVC/Min ETBF tumors cluster with the Min mock tumors. The WT/Min ETBF 
tumors fall on a distinct arm from the other samples suggesting that their DNA 
hypermethylation alterations are distinct from all other tumors types, including the ETBF-
induced tumors from Msh2l/lVC/Min mice. Plots of the DNA methylation data for Hoxa5 
and Polg demonstrate the reduction of promoter CpG island hypermethylation in 
Msh2l/lVC/Min ETBF tumors compared to WT/Min ETBF tumors (Figure 5C). This 
observation was validated at several candidate genes with tumor suppressive function 
including Hoxa5, Polg, Runx3, and Stx11 (Figure S5 A, B). Both the mock and ETBF 
Msh2l/lVC/Min tumors had many hypomethylated DMRs relative to Msh2l/lVC/Min mock 
epithelium (Figure 5B and Table S2), suggesting that the losses of methylation are general to 
the tumorigenesis process in these mice.
Furthermore, we examined the effect of loss of Msh2 on mRNA expression of several 
candidate genes in tumors that formed at sites of ETBF-mediated inflammation. 
Interestingly, loss of Msh2 partially restored expression of candidate genes in tumors that 
formed at sites of ETBF-mediated inflammation, including Cdx1, Fut4, Hoxa5, Polg, Runx1 
and Runx3 (Figure 5D).
As mentioned, it has been widely reported that there is a global loss of DNA methylation in 
cancer. Therefore, we examined the effect of Msh2 deficiency on global CpG DNA 
methylation. Consistent with what is observed in humans, the WT/Min ETBF tumors 
exhibited a global loss of DNA CpG methylation. Interestingly, loss of Msh2 restored total 
CpG methylation back to mock epithelium levels (Figure 5D). Thus, not only did loss of 
Msh2 reduce regional hypermethylation alterations genome-wide, it also reduced ETBF-
mediated global DNA hypomethylation. These results reinforce the notion that MSH2 is an 
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essential player in both the recruitment of epigenetic proteins to chromatin during the early 
stages of inflammation and in the permanent silencing of several TSGs in tumors that form 
at sites of ETBF-mediated inflammation and oxidative DNA damage.
Discussion
Many studies have demonstrated a strong relationship between inflammation and epigenetic 
alterations (1). Although the mechanism connecting the two is not well understood, 
oxidative damage is a prominent feature associated with both. Based on previous work by 
our group, we hypothesized that sustained and/or repeated oxidative damage to chromatin, 
during inflammation, may result in epigenetic silencing (O’Hagan 2011). To test this 
hypothesis we used an established mouse model of inflammation-induced colon 
tumorigenesis. The bacterium ETBF has been shown to rapidly induce acute colitis and 
tumorigenesis in Min mice that resembles the pathology observed in humans with colorectal 
cancer (11, 41). Importantly, several studies revealed a strong association between ETBF 
colonization in the gut and colorectal cancer incidence in humans suggesting that this mouse 
model is highly relevant to human colon carcinogenesis and an appropriate model to use to 
investigate the mechanism underlying how inflammation initiates DNA methylation 
alterations (42, 43).
Whether ETBF-mediated inflammation can induce DNA methylation alterations in humans 
remains to be determined; however, colitis, which can be induced by ETBF, is strongly 
associated with aberrant DNA methylation alterations in humans (44). Furthermore, others 
have demonstrated an association between bacterial infection and DNA methylation 
alterations in both animals and humans. A well-characterized example is induction of 
aberrant DNA methylation alterations and gastric cancer in Mongolian gerbils due to 
exposure to the bacterium Helicobacter pylori (45). A human study reported that the gastric 
mucosa of H. pylori infected individuals had higher methylation levels at 8 marker CpG 
islands compared to uninfected individuals (46). The results presented in our study are 
highly consistent with these findings in animals and humans in that compared to mock colon 
epithelium, ETBF-induced tumors have altered DNA methylation, including 
hypermethylation of promoter CpG islands of several TSGs. Furthermore, the epithelium 
surrounding the tumors in ETBF-infected mice had more DNA hypermethylation alterations 
than the mock epithelium but still considerably fewer hypermethylation changes compared 
to ETBF tumors, confirming an inflammation-produced field effect that has previously been 
demonstrated (1). Interestingly, the DNA methylation pattern observed in ETBF-induced 
tumors was remarkably similar to what is observed in human cancers, including CRC, 
namely global hypomethylation concomitant with focal hypermethylation. As has been 
shown in human CRC, the DNA hypermethylation changes observed in our study occurred 
at regions that are bivalent in embryonic stem cells and genes associated with DMRs were 
enriched in processes associated with development and differentiation.
Min mice spontaneously develop occasional tumors in the colon. Conveniently, this allowed 
us to compare DNA methylation changes in inflammation-induced tumors to changes in 
non-inflammation-induced tumors. There were very few hypermethylation changes in the 
mock tumors compared to the ETBF tumors. A critical point here is that the vast majority of 
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DNA hypermethylation alterations observed in our study in the ETBF-induced tumors are 
specifically driven by ETBF or ETBF-mediated inflammation and this is highly consistent 
with what has been reported in similar animal models and in humans.
Niwa et al. ruled out the possibility that H. Pylori itself is responsible for the induction of 
DNA methylation alterations in the gastric mucosa of Mongolian gerbils, and confirmed that 
innate immune-mediated inflammation resulting from H. pylori is the culprit (45). However, 
the molecular mechanism that underlies how inflammation initiates epigenetic alterations in 
cancer is not well understood. Our hypothesis in this study is that innate immune-mediated 
inflammation, caused by ETBF, induces oxidative DNA damage and thereby triggers early 
transient silencing of genes, rendering them susceptible to stable silencing through DNA 
methylation. Importantly, at the time point when ETBF-infection induces robust oxidative 
DNA damage, we see increased enrichment of EZH2 at promoters of genes that become 
methylated in tumors that form at sites of inflammation, coinciding with reduced expression. 
We demonstrate that Msh2 deletion in intestinal epithelial cells abrogates the ETBF-
mediated recruitment of epigenetic proteins to chromatin and restores expression of 
candidate genes. Knowing that we now had a system where we could block the recruitment 
of epigenetic proteins to sites of oxidative DNA damage without affecting the inflammatory 
response or DNA damage levels, we could determine if DNA hypermethylation in the 
inflammation-induced tumors depends on this early epigenetic response to oxidative 
damage. Importantly, Msh2 deletion reduced ETBF-mediated genome-wide 
hypermethylation alterations and reversed ETBF-induced global hypomethylation in tumors 
that formed at sites of inflammation.
Intriguingly, loss of Msh2 led to increased tumorigenesis in response to ETBF, despite a lack 
of DNA hypermethylation and reexpression of TSGs. This result suggests that another 
mechanism, independent of aberrant epigenetic alterations, can drive tumorigenesis in the 
context of ETBF-infection. We speculate that increased genomic defects, due to MSI, 
underlie tumorigenesis in Msh2l/lVC/Min mice exposed to ETBF. To our advantage, the fact 
that Msh2l/lVC/Min mice develop tumors in response to ETBF allowed us to elucidate a 
mechanism to explain how epigenetic alterations occur during tumorigenesis, a task that 
could not have been achieved if tumors did not form in these mice. Whether or not DNA 
hypermethylation changes are necessary to drive inflammation-induced tumorigenesis in the 
context of a normal mutational burden needs to be studied further.
It remains to be determined precisely how the early ETBF-induced epigenetic alterations 
observed in our model are maintained and converted into permanent epigenetic alterations in 
tumors that form at sites of inflammation. We speculate that, in addition to the epithelial 
cells, these alterations occur and persist in the intestinal stem cells, which are known to 
eventually go on to transform into tumor cells (47). This hypothesis is supported by the 
observation that some epigenetic alterations that occur early in stem cells lead to permanent 
silencing of TSGs thereby contributing to predisposing the cell to malignant transformation 
(48).
The work described here provides a mechanism to explain how inflammation, in this case 
inflammation mediated by ETBF, a pathogen associated with CRC in humans, causes early 
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epigenetic alterations, some of which persist in tumors that form at sites of inflammation. A 
challenge in elucidating the mechanism by which inflammation initiates epigenetic 
alterations, is that it is difficult to selectively modulate responses caused by inflammation 
without also modulating the initial inflammatory response altogether. We were able to 
prevent inflammation-induced hypermethylation in tumors without modulating the initial 
inflammatory response by using mice lacking Msh2. Our findings suggest a role for MSH2 
in initiating early ETBF-mediated epigenetic alterations and maintaining DNA methylation 
alterations that occur in the ETBF-induced tumors. A recent study demonstrated that MSI 
tumors from patients with Lynch syndrome, a disease in which patients harbor genetic 
mutations in MMR genes and eventually develop CRC, have less DNA hypomethylation and 
fewer regional hypermethylation alterations (49), analogous to what we observed in our 
study.
While in sporadic CRC loss of expression of the MMR protein MLH1 is associated with 
CpG Island Methylator Phenotype (CIMP), we demonstrate here that loss of MSH2 or 
MSH6 plays an opposite role. This finding is supported by CRC TCGA data where, of the 
hypermutated tumors studied, those with MLH1 methylation were CIMP, but those with 
mutations in MSH2/6/3 and WT MLH1 expression were not CIMP (9).
The results presented herein fill in critical gaps in our understanding of the relationship 
between inflammation and epigenetic alterations by elucidating a role for inflammation-
induced DNA damage and consequent MMR in initiating cancer-specific epigenetic 
alterations during tumorigenesis. Knowledge gained from this study has notably increased 
our understanding concerning how epigenetic alterations are initiated during tumorigenesis 
in the colon and this information can likely be extrapolated to other types of cancer. 
Interestingly, regions with DNA hypermethylation in the inflammation-induced tumors were 
surprisingly consistent between tumors from different mice and different experimental 
cohorts suggesting a strong selective pressure for these silencing events. We hypothesize that 
the mechanism of DNA hypermethylation is similar in other inflammatory-driven epithelial 
cancers, but the specific genes silenced may differ depending on the selective pressures of 
tumorigenesis in other tissues. Understanding the mechanism of initiation of DNA 
methylation changes will allow the scientific community to therapeutically target 
inflammation-induced epigenetic changes and potentially reduce the cancer risk of 
individuals with chronic inflammatory diseases.
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Figure 1. Inflammation-induced tumors have unique DNA hypermethylation alterations
A) Unsupervised hierarchical clustering of MBD-seq z-scores of the 239 regions with DNA 
hypermethylation in one of the tumor groups relative to mock epithelium (rows). Each 
column corresponds to the indicated epithelium or tumor sample. The color of each cell 
reflects the degree of methylation. All tissue samples were collected 8 weeks after 
inoculation (N=3 mock and ETBF epithelium and mock tumors; N=5 ETBF tumors). B) 
Tukey box plots of z-scores of regions with gains or losses of methylation in ETBF or mock 
tumors relative to mock epithelium. C) MBD-seq data at representative regions for indicated 
epithelium and tumors. In vitro methylated DNA (IVD) serves as a positive control. D) 
Pyrosequencing of bisulfite treated DNA from indicated tissue in promoters of candidate 
genes. Mean +/− SEM. N≥6. *p<0.05. E) qMSP of samples as in D. *p<0.05 compared to 
mock epithelium. #p<0.05 compared to ETBF epithelium. F) Gene expression by qPCR of 
candidate genes relative to mock epithelium. Mean +/− SEM. N≥6. *, # as in E. See also 
Figure S1.
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Figure 2. Genes that undergo methylation in tumors have reduced expression at the time point of 
highest oxidative damage
A) 8-oxoG dot blot of DNA extracted from distal colon epithelium from mock or ETBF-
inoculated mice, N=3. Bar graph of densitometry determined using ImageJ for dots. Mean +/
− SEM. B) 8-oxoG staining by flow cytometry of Epcam-positive cells from mice treated as 
in A. C) Expression of candidate genes by qPCR in distal colon epithelium from mice at the 
indicated days post-mock or ETBF. Mean +/− SEM. N=5. *p<0.05. D) EZH2, IgG and E) 
H3K27me3 enrichment by ChIP relative to input at promoters of indicated genes in distal 
colon epithelium from mice 2 days post-mock or ETBF. Mean +/− SEM. N=3. *p<0.05. See 
also Figure S2.
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Figure 3. Acute inflammation-induced epigenetic changes are dependent on MSH2
A) IgG or Ezh2 co-IP from distal colon epithelial cells 2 days post-mock (M) or ETBF (E) 
inoculation. B) Anti-MSH2 IHC of the distal colon of WT or Msh2l/lVC mice 2 days post-
mock or ETBF. Images are representative of staining from 3 mice per group. C) Proteins that 
are tightly bound to chromatin (tight chromatin) from epithelium as in A. D) Expression of 
candidate genes by qPCR in distal colon epithelial cells from mice at 2 days post-mock or 
ETBF. Mean +/− SEM. N=5–7. *p<0.05. E) Anti-γ-H2AX IHC of the same tissue sections 
as in B with quantification of γ-H2AX foci per crypt. N≥45 crypts. Mean+/−SEM. *p<0.05 
by Tukey’s multiple comparison test. See also Figure S3.
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Figure 4. Inflammation-induced tumorigenesis is increased in the distal colon of mice with 
altered Msh2 expression
A) PCA analysis of 16S microbiome sequencing of DNA from stool samples from WT/Min 
or Msh2l/lVC/Min mice 8 weeks post mock or ETBF. B) Heatmap representing the 
unsupervised hierarchical clustering of 65 OTUs found to be differentially abundant by one 
pair-wise comparison (rows) in individual stool samples (columns) from indicated mice 
treated as in A. C) ETBF abundance in stool relative to total bacterial DNA by qPCR. 
Symbols represent data from individual mice. Horizontal line is mean +/− SEM. N≥13. 
*p<0.05. D) Tukey box plots of tumor counts by cm in WT/Min or Msh2l/lVC/Min mice 8 
weeks after mock or ETBF. N≥8. *p<0.05. E) Whole cell protein lysate from distal colon 
epithelium or tumors from mice of the indicated genotypes 8 weeks post-mock or ETBF 
inoculation, respectively, were blotted for the indicated proteins. See also Figure S4.
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Figure 5. Msh2 deficiency abrogates inflammation-induced epigenetic changes in tumors
A) Unsupervised hierarchical clustering of MBD-seq z-scores of regions with increased 
DMRs in one of the tumor groups relative to mock epithelium (rows). Each column 
corresponds to the indicated epithelium or tumor sample. The color of each cell reflects the 
degree of methylation. B) Numbers of DMRs for the indicated tumor group relative to the 
corresponding mock epithelium that overlap between comparisons. Green and red numbers 
are hypomethylated and hypermethylated regions, respectively. C) MBD-seq data at 
representative regions for indicated epithelium and tumors 8 weeks post-inoculation. D) 
Expression of candidate genes by qRTPCR relative to WT/Min ETBF tumors. Mean +/− 
SEM. N=5. *p<0.05. E) Total 5-mC content of DNA. Mean +/− SEM. N=3 mock, N=6 
tumor. *p<0.05. See also Figure S5.
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Table 1
Number of 500 bp regions from the MBD-seq data that are statistically different in the indicated comparisons.
Gains Losses Total
Min mock tumor X Min mock epithelium 6 700 706
Min ETBF epithelium X Min mock epithelium 40 265 305
Min ETBF tumor X Min mock epithelium 203 194 397
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